Second, while our studyincluded all patients with T2DM and gout regardless of their antidiabetictreatment regimen, this may have introduced some heterogeneity within thecontrol group, particularly if a higher proportion of insulin users was includeddue to advanced disease progression. The gene discussed is INS; the disease is gout.